GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life.
The post GSK Gets Closer to Bringing Patients a Functional Cure for Chronic Hepatitis B appeared first on MedCity News.
